Functional alterations of myeloid cells during the course of Alzheimer’s disease

[1]  Christopher C. Overall,et al.  Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia , 2018, The Journal of experimental medicine.

[2]  A. Salminen,et al.  The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer’s disease , 2018, Cellular and Molecular Life Sciences.

[3]  J. Poirier,et al.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis , 2018, Journal of Alzheimer's disease : JAD.

[4]  S. Wong,et al.  The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence , 2018, Cell Death & Disease.

[5]  D. Standaert,et al.  Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease , 2018, Experimental Neurology.

[6]  R. Bazinet,et al.  Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review , 2017, Molecular Psychiatry.

[7]  G. Pawelec,et al.  Role of the peripheral innate immune system in the development of Alzheimer's disease , 2017, Experimental Gerontology.

[8]  A. West,et al.  α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration , 2017, Acta neuropathologica communications.

[9]  A. Cuello.  Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum? , 2017, Trends in pharmacological sciences.

[10]  T. Kanekiyo,et al.  Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease , 2017, International journal of molecular sciences.

[11]  G. Pawelec,et al.  Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnestic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients , 2017, Front. Immunol..

[12]  A. Hoerauf,et al.  Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections. , 2017, Immunobiology.

[13]  Shanker Kalyana-Sundaram,et al.  Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes , 2017, JAMA neurology.

[14]  J. Taboas,et al.  Phenotype, function, and differentiation potential of human monocyte subsets , 2017, PloS one.

[15]  Petra C. Kienesberger,et al.  Changes in Circulating Monocyte Subsets (CD16 Expression) and Neutrophil-to-Lymphocyte Ratio Observed in Patients Undergoing Cardiac Surgery , 2017, Front. Cardiovasc. Med..

[16]  Paul Edison,et al.  An early and late peak in microglial activation in Alzheimer’s disease trajectory , 2017, Brain : a journal of neurology.

[17]  Marco Prinz,et al.  The role of peripheral immune cells in the CNS in steady state and disease , 2017, Nature Neuroscience.

[18]  P. Libby,et al.  The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans , 2016, Scientific Reports.

[19]  B. Fontaine,et al.  Distinct inflammatory phenotypes of microglia and monocyte‐derived macrophages in Alzheimer's disease models: effects of aging and amyloid pathology , 2016, Aging cell.

[20]  R. Ransohoff,et al.  Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus , 2016, Proceedings of the National Academy of Sciences.

[21]  J. Kipnis.  Multifaceted interactions between adaptive immunity and the central nervous system , 2016, Science.

[22]  Jeih-San Liow,et al.  11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease , 2016, Neurobiology of Aging.

[23]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[24]  G. Pawelec,et al.  Peripheral Immune Signatures in Alzheimer Disease. , 2016, Current Alzheimer research.

[25]  R. Mukherjee,et al.  Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous , 2015, Scientific Reports.

[26]  S. Rivest,et al.  The dynamics of monocytes and microglia in Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[27]  D. Ingram,et al.  Clinical significance of monocyte heterogeneity , 2015, Clinical and Translational Medicine.

[28]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[29]  P. Sinha,et al.  Cross‐talk among myeloid‐derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors , 2014, Journal of leukocyte biology.

[30]  J. Kassubek,et al.  Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients , 2014, Acta Neuropathologica.

[31]  H. Weiner,et al.  Differential roles of microglia and monocytes in the inflamed central nervous system , 2014, The Journal of experimental medicine.

[32]  S. Gauthier,et al.  Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging , 2014, Journal of Neuroinflammation.

[33]  Marco Prinz,et al.  Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease , 2014, Nature Reviews Neuroscience.

[34]  Hong Wang,et al.  Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases , 2014, Biomarker Research.

[35]  M. Alberoni,et al.  A complex proinflammatory role for peripheral monocytes in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[36]  Manasi Malik,et al.  CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing , 2013, The Journal of Neuroscience.

[37]  V. Perry,et al.  Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration , 2013, Seminars in Immunopathology.

[38]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[39]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[40]  T. Nakahata,et al.  Robust and Highly-Efficient Differentiation of Functional Monocytic Cells from Human Pluripotent Stem Cells under Serum- and Feeder Cell-Free Conditions , 2013, PloS one.

[41]  V. Apostolopoulos,et al.  Myeloid derived suppressor cells and their role in diseases. , 2013, Current medicinal chemistry.

[42]  F. Ginhoux,et al.  Origin and differentiation of microglia , 2013, Front. Cell. Neurosci..

[43]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[44]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[45]  D. Frenkel,et al.  Inflammatory events at blood–brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease , 2012, Epilepsia.

[46]  W. Banks,et al.  Neuroinflammation: A Common Pathway in CNS Diseases as Mediated at the Blood-Brain Barrier , 2012, Neuroimmunomodulation.

[47]  C. Colton,et al.  Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses , 2011, ASN neuro.

[48]  Wing-Cheong Wong,et al.  Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. , 2011, Blood.

[49]  M. Manns,et al.  Myeloid derived suppressor cells in human diseases. , 2011, International immunopharmacology.

[50]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[51]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[52]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[53]  Xiao-Hong Sun,et al.  Monocytes and Alzheimer’s disease , 2011, Neuroscience bulletin.

[54]  Je-in Youn,et al.  The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity , 2010, European journal of immunology.

[55]  Silvano Sozzani,et al.  Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.

[56]  P. Mcgeer,et al.  Inflammation in transgenic mouse models of neurodegenerative disorders. , 2010, Biochimica et biophysica acta.

[57]  E. Halpern,et al.  Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage , 2010, Journal of leukocyte biology.

[58]  P. Carvey,et al.  The blood–brain barrier in neurodegenerative disease: a rhetorical perspective , 2009, Journal of neurochemistry.

[59]  T. Town,et al.  CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease? , 2009, Journal of Neuroimmune Pharmacology.

[60]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[61]  C. Geula,et al.  Ccr2 Deficiency Impairs Microglial Accumulation and Accelerates Progression of Alzheimer's Disease , 2007 .

[62]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[63]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[64]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[65]  B. Brew,et al.  Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification , 2004, Journal of leukocyte biology.

[66]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[67]  J. Brion,et al.  Neurofibrillary Tangles and Alzheimer’s Disease , 1998, European Neurology.

[68]  K. Blennow,et al.  A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.

[69]  J. Wegiel,et al.  Amyloid Angiopathy and Blood–Brain Barrier Changes in Alzheimer's Disease a, b , 1997, Annals of the New York Academy of Sciences.

[70]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[71]  I Karlsson,et al.  Blood‐brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors , 1990, Acta neurologica Scandinavica.

[72]  Gösta Bucht,et al.  Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of alzheimer type and multi-infarct dementia , 1983, Journal of the Neurological Sciences.

[73]  H. Wiśniewski,et al.  Evidence for Blood‐Brain Barrier Changes in Senile Dementia of the Alzheimer Type (SDAT) , 1982, Annals of the New York Academy of Sciences.

[74]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[75]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[76]  E B Larson,et al.  Cognitive impairment: dementia and Alzheimer's disease. , 1992, Annual review of public health.